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Abstract
Background:  Late onset Alzheimer's disease (LOAD) is a neurodegenerative disorder
characterised by the deposition of amyloid plaques and neurofibrillary tangles in the brain and is the
major cause of dementia. Multiple genetic loci, including 10q, have been implicated in LOAD but to
date, with the exception of APOE, the underlying genes have not been identified. HECTD2 maps to
10q and has been implicated in susceptibility to human prion diseases which are also
neurodegenerative conditions associated with accumulation of misfolded host proteins. In this
study we test whether the HECTD2 susceptibility allele seen in prion disease is also implicated in
LOAD.
Methods: DNA from 320 individuals with Alzheimer's disease and 601 controls were genotyped
for a HECTD2 intronic tagging SNP, rs12249854 (A/T). Groups were further analysed following
stratification by APOE genotype.
Results: The rs12249854 minor allele (A) frequency was higher (5.8%) in the Alzheimer's disease
group as compared to the controls (3.9%), however, this was not statistically significant (P =
0.0668). No significant difference was seen in minor allele frequency in the presence or absence of
the APOE ε4 allele.
Conclusion: The common haplotypes of HECTD2, tagged by rs12249854, are not associated with
susceptibility to LOAD.
Background
Alzheimer's disease (AD) is the most common form of
dementia affecting millions of people worldwide [1]. The
decline in cognitive ability is accompanied by characteris-
tic pathological changes in the brain which include depo-
sition of extracellular amyloid plaques composed of β-
amyloid (Aβ) [2] and the accumulation of intracellular
neurofibrillary tangles (hyperphosphorylated tau) [3].
Mutations in three genes, β-amyloid precursor protein
(APP), presenilin-1 (PSEN1) and presenilin-2 (PSEN2),
have been found in early-onset autosomal dominant AD
[4-6]. In contrast, the majority of AD cases have a later age
of onset (>65 years) [1] and although heritability is high,
there are multiple environmental and genetic risk factors
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with no clear Mendelian pattern of inheritance [7]. To
date, the main genetic risk factor for late onset Alzheimer's
disease (LOAD) is the apolipoprotein E gene (APOE)
where the ε4 allele is over-represented in affected individ-
uals (50%) compared to controls [8]. The partial pene-
trance for ε4 suggests that other genes are also likely to be
important in the development of LOAD [9].
Linkage studies, and more recently genome-wide associa-
tion studies (GWAS), have provided evidence to support a
role for multiple genes in the aetiology of LOAD [9,10].
Difficulties in replicating findings across multiple studies
still leaves considerable uncertainty in defining the
genetic risk factors. Significant evidence exists for a sus-
ceptibility locus on chromosome 10q [11-14], however,
there are conflicting reports on its precise location and to
date no clear association to an individual gene has been
demonstrated. Insulin degrading enzyme (IDE) is
encoded by a gene that maps to Chr 10q and has been
implicated in the breakdown and clearance of extracellu-
lar Aβ [15]. Although there is contradictory evidence for
an allelic association between IDE and AD [16-18] a link-
age study carried out in 435 multiplex AD families found
significant linkage to markers adjacent to IDE (D10S583
and D10S1671) [11,19].
HECTD2  encodes an E3-ubiquitin ligase protein and
maps within 1 Mb of D10S583 and IDE. HECTD2 has
been linked to prion disease incubation time in mice and
a susceptibility haplotype has been associated with
human prion disease [20]. Prion diseases, like AD, are
neurodegenerative disorders with a complex aetiology.
Mutations in the prion protein gene (PRNP) cause the
inherited prion diseases [21,22] and coding polymor-
phisms in the prion protein (PrP) are associated with sus-
ceptibility to acquired and sporadic Creutzfeldt-Jakob
disease (CJD), kuru and influence age of onset in some
inherited prion diseases [23-25]. Similarly to LOAD,
acquired and sporadic CJD have a complex non-Mende-
lian genetic component where there is evidence for the
role of multiple genes [26-29]. Prion diseases also share
some of the neuropathologic hallmarks of AD and are
considered to be diseases of protein misfolding where
abnormal forms of PrP accumulate in the brain often in
the form of amyloid plaques [21,30].
The similarities between AD, prion diseases and other
neurodegenerative disorders suggest that common molec-
ular mechanisms and pathways may be involved. The
ubiquitin-proteosome system is one such example that
has been implicated in the pathogenesis of several neuro-
degenerative diseases which show an accumulation of an
abnormally folded protein including AD and prion dis-
ease [31-33]. The substrate and exact function of HECTD2
are unknown but by homology to other family members
it is thought to function as an E3 ubiquitin ligase, catalys-
ing the transfer of ubiquitin to specific proteins, thus tar-
geting them for degradation by the proteosome.
Mutations in an E3 ubiquitin ligase, parkin, are associated
with forms of inherited Parkinson's disease [34].
The location of HECTD2 on Chr 10q, its association with
another neurodegenerative proteinopathy and its involve-
ment in the ubiquitin-proteosome pathway suggest that
HECTD2 is a suitable candidate gene for LOAD suscepti-
bility. The aim of this study was therefore to test whether
the HECTD2 risk allele seen in CJD is also a susceptibility
factor for non-familial AD.
Methods
Human samples
The clinical and laboratory studies were approved by the
local research ethics committee of University College Lon-
don Institute of Neurology and National Hospital for
Neurology and Neurosurgery. Most of the samples were
obtained with written consent from patients or next of
kin, however, for archival samples, where this was not
available, specific approval was obtained from the local
ethics committee.
Alzheimer's disease
Patient samples were derived from the MRC Prion Unit
sample collection based on a clinician's diagnosis of AD
(n = 320). The majority of samples were referred to the
Unit for APP, PSEN1 or PSEN2 gene sequencing although
not all genes were tested in all patients, because for exam-
ple, some samples were referred prior to the discovery of
presenilin gene mutations as causal in AD. Samples with
causal mutations were excluded. Consequent upon
patient ascertainment, the sample collection is enriched
for unexplained early onset AD. Those of known non-
white Caucasian ethnicity were excluded. Average age at
time of sampling was 53, 47% were male. Ethical
approval for the study was given by the University College
London Hospitals NHS Trust Local Ethics Committee.
APOE genotypes were obtained for n = 316 samples. Allele
frequencies for ε2,  ε3 and ε4 were 3.6%, 62.1% and
34.3% respectively. 55.1% of individuals had one or more
ε4 alleles which is consistent with other reports of LOAD.
UK controls
116 individuals were recruited from the National Blood
Service (NBS). Individuals were of white-British ethnicity
and the mean of age at sampling was 34 years (range 18-
64); 56% were male. DNA was extracted from whole
blood. Further UK control samples (n = 485) were pur-
chased from the European Collection of Cell Cultures
(ECACC) Human Random control (HRC) DNA panels
consisting of randomly selected, non-related UK Cauca-BMC Medical Genetics 2009, 10:90 http://www.biomedcentral.com/1471-2350/10/90
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sian blood donors. Total number of UK controls was n =
601.
DNA extraction
Genomic DNA was usually extracted from peripheral
blood using a Nucleon Genomic DNA Extraction Kit
according to the manufacturer's instructions; for a small
number of brain tissue samples we used a phenol-chloro-
form method. Amplified DNA, using either multiple dis-
placement amplification (Geneservice, Cambridge, UK)
or fragmentation-PCR methods (Genomeplex, Sigma),
was used for a small number <10% of samples. Samples
were checked for degradation on 1% agarose gel and
stored at 50 ng/μl in 10 mM Tris-EDTA buffer.
Genotyping
For rs12249854 a pre-designed allelic discrimination assay
was purchased from Applied Biosystems and used accord-
ing to the manufacturer's instructions. All reactions were
carried out in 5 μl on a 7500 Fast Real-time PCR System
(Applied Biosystems) using RoxMegaMix Gold (Micro-
zone Ltd). Cycling conditions were 95°C 5 minutes; 95°C
15 s, 60°C 60 s for 40 cycles.
APOE genotyping
APOE  genotyping was performed by Cfo1 restriction
endonuclease digestion of PCR amplicon and size differ-
entiation by agarose gel electrophoresis [35].
Statistical genetics
Association was tested using the Pearson Chi-squared test
(SPSS, SPSS Inc.). Additional permutation tests were car-
ried out using PLINK [36].
Results
We have previously shown that strong linkage disequilib-
rium (LD) extends across the whole of the HECTD2 gene
and interrogation of HapMap data suggests that this block
of LD does not extend into neighbouring genes [20]. It is
therefore possible to tag the haplotype associated with
susceptibility to prion disease with a single nucleotide
polymorphism (SNP), rs12249854  (A/T) that occurs
within intron 1 of HECTD2. rs12249854 was genotyped in
a panel of 320 samples from patients with a definite or
probable diagnosis of AD and no known mutations in
APP, PSEN1 or PSEN2. APOE genotypes were available for
316 individuals and showed enrichment for the ε4 allele
(55.1% of individual have one or more ε4 allele). Geno-
types were compared with those of a previously geno-
typed UK control group (n = 601) that were ethnically
matched [20].
The rs12249854 minor allele (A) frequency was higher
(5.8%) in the AD group as compared to the controls
(3.9%), however, this was not significant (P = 0.0668,
Chi-squared test, allelic odds ratio = 1.5 (95% CI = 0.97-
2.3)) (Table 1). In addition to looking at the allele fre-
quencies we also looked at genotype specific effects. The
AA genotype is rare and was not observed in the control
group. While two AA individuals were seen in the AD
group, this was not significant (P = 0.0648, Chi squared
test). Because the expected minor allele frequency is low,
the Chi-squared test may be unreliable therefore we
implemented 1,000,000 permutations using PLINK [36]
for both allelic (empirical P = 0.079) and genotypic
(empirical P = 0.051) models. Assuming perfect linkage
disequilibrium between the genotyped and functional
SNP and a multiplicative risk model, our sample was 80%
powered to detect a heterozygous genotype relative risk of
1.8 with a type I error of 0.5% [37]. The APOE ε4 allele is
a major risk factor for LOAD therefore we also stratified
our samples by presence or absence of the ε4 allele. The
minor allele frequency was 5.7% and 5.6% in the ε4 and
non-ε4 group respectively. Although not significant, it is
interesting to note that both AA individuals were also
homozygous for the ε4 allele.
Discussion
LOAD is a major cause of dementia and is becoming
increasingly important in ageing populations. Identifying
the genetic susceptibility factors may help to identify
those at risk of developing the disease and the effective
targeting of future preventative treatments. With the
exception of APOE, no genes have been conclusively
shown to be susceptibility factors for LOAD. In this study,
we genotyped a panel of AD patients and looked for an
Table 1: Statistical analysis of HECTD2 marker rs12249854




AA 2 (0.6) 0 (0.0) 0.0648 0.051
TA 33 (10.3) 47 (7.8)
TT 285 (89.1) 554 (92.2)
A 37 (5.8) 47 (3.9) 0.0668 0.079
T 603 (94.2) 1155 (96.1)
P-values were calculated using a chi-squared test and as an alternative we also implemented 1,000,000 permutations using PLINK [36]. http://
pngu.mgh.harvard.edu/purcell/plink/BMC Medical Genetics 2009, 10:90 http://www.biomedcentral.com/1471-2350/10/90
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association with a HECTD2 SNP previously shown to be
associated with prion disease [20]. Although the minor
allele frequency was higher in the AD samples than the
controls this was not significant. This result suggests that
in spite of being a promising candidate, HECTD2 is not
implicated in AD. Although a negative study, our data do
not totally exclude HECTD2. Our study assumes that, as
for prion disease, a common variant of HECTD2 is the
susceptibility allele. However, multiple rare variants
would not be detectable by our tagging SNP. Re-sequenc-
ing of HECTD2  in a panel of AD samples would be
required to exclude this possibility.
LOAD has a complex aetiology and collections of patient
samples may be highly heterogeneous, therefore, very
large sample sizes may be required to detect small effects.
The heterogeneity of the disease phenotype and the vary-
ing inclusion criteria used in different studies may con-
tribute to the difficulties in replicating promising findings
from different centres.
Prevalence figures suggest that LOAD affects 20% of peo-
ple aged 75-84 years and rising in older age groups [1]. No
detailed age information was available for our control
group, however, samples were taken from current blood
donors which suggests that although currently unaffected
by dementia it is likely that a significant proportion will
develop AD later in life and are therefore likely to carry
susceptibility alleles. This may confound our findings.
Large cohorts of non-demented elderly individuals are dif-
ficult to obtain, however, their use would increase the
power to detect genetic susceptibility factors.
Several studies have reported evidence for a LOAD suscep-
tibility locus on Chr 10q, however, the exact locations
vary and the regions are frequently broad with added
uncertainty about the number of genes involved. It is
hoped that results from large, well controlled and repli-
cated GWAS studies will successfully identify the suscepti-
bility alleles on Chr 10q and at other loci across the
genome.
Conclusion
Based on linkage data, association with another neurode-
generative disease and association with the ubiquitin-pro-
teosome system, HECTD2  is a promising candidate
susceptibility factor for LOAD. In this study we have gen-
otyped a panel of AD patients for the HECTD2  SNP
rs12249854 (A/T) and compared this data to a previously
genotyped control population. The minor allele (A) fre-
quency was increased (5.8%) compared to controls
(3.9%), however, this was not statistically significant. We
were unable to exclude weak or moderate effects on AD
risk. No differences were seen when the population was
further stratified by APOE ε4 genotype. Based on this data
we conclude that the common variants of HECTD2, as
detected by our tagging SNP, are unlikely to be strong sus-
ceptibility factors for LOAD in the UK population.
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